Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620683 | 1.00 | BCHE (0.35) | BCHECYP11B2CYP19A1ACHEMAPT | |
| SCHEMBL5233554 | 0.94 | ACHE (0.37) | BCHECYP11B2CYP19A1ACHETBXAS1 | |
| SCHEMBL29429214 | 0.94 | ACHE (0.37) | BCHECYP11B2CYP19A1ACHETBXAS1 | |
| Carbamic Acid SCHEMBL16823528 | 0.89 | KDM4E (0.41) | BCHECYP11B2MAPTKDM4ETBXAS1 | |
| SCHEMBL29550114 | 0.87 | — | — | |
| SCHEMBL157325 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL29651204 | 0.85 | ALDH1A1 (0.35) | BCHEACHEKDM4ECYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31159090 | 0.85 | ALDH1A1 (0.35) | BCHEACHEKDM4ECYP1A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27985804 | 0.85 | ALDH1A1 (0.35) | BCHEACHEKDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL28659623 | 0.82 | CYP19A1 (0.32) | CYP19A1ACHETBXAS1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| WO-2024251133-A1 | HETEROCYCLIC COMPOUND AS α5-GABAA RECEPTOR MODULATOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2024-12-12 | — | — | WO | claimed |
| CN-119080754-A | As alpha 5-GABAAHeterocyclic compounds of receptor modulators and uses thereof | 武汉人福创新药物研发中心有限公司 | 2024-12-06 | — | — | CN | claimed |
| WO-2024245156-A1 | HETEROCYCLIC COMPOUND ACTING AS α5-GABAA RECEPTOR REGULATOR | 武汉人福创新药物研发中心有限公司 | 2024-12-05 | — | — | WO | claimed |
| CN-119019425-A | Alpha 5-GABAAHeterocyclic compounds as receptor modulators | 武汉人福创新药物研发中心有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118994149-A | Efficient HPK1 degradation agent compound and preparation method and application thereof | 杭州阿诺生物医药科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-12138263-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | claimed |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | claimed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | claimed |
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-24 | — | — | US | claimed |
| WO-2019180646-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-09-26 | — | — | WO | claimed |
| WO-2019183364-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| WO-2019165073-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2019-08-29 | — | — | WO | claimed |
| WO-2019067843-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | claimed |
| WO-2018218133-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| CN-104610256-A | Method for preparing tetrahydro-1,5-naphthyridine compound and prepared chiral product thereof | CHINESE ACAD INST CHEMISTRY | 2015-05-13 | — | — | CN | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAPB, VAT1 | BCHE 2964/4885CYP11B2 667/4885CYP19A1 1080/4885 |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | BCHE 4827/4885CYP11B2 3789/4885CYP19A1 3098/4885 |
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | BCHE 1729/4885CYP11B2 3303/4885CYP19A1 3978/4885 |
| US-12138263-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof | PTPN2, PTPN5, PTPRJ | BCHE 4508/4885CYP11B2 1695/4885CYP19A1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.